Six Flags stock rises after appointing John Reilly as new CEO
Casdin Partners, a group of entities related to Casdin Capital, reported purchasing shares of Standard BioTools Inc (NASDAQ:LAB) between November 18 and November 20, 2025. The purchases totaled $1.37 million, with prices ranging from $1.2342 to $1.3028 per share. According to InvestingPro data, LAB currently trades at $1.28, with a market capitalization of approximately $494 million.
On November 18, the entities bought 275,000 shares. The next day, November 19, they acquired 350,000 shares. On November 20, they purchased an additional 450,000 shares. These purchases come at a time when Standard BioTools shows a strong financial position with more cash than debt on its balance sheet and a healthy current ratio of 4.38.
Following these transactions, Casdin Partners Master Fund, L.P. directly owns 64,050,000 shares. Casdin Private Growth Equity Fund II, L.P. directly owns 13,939,637 shares, Casdin Private Growth Equity Fund, L.P. directly owns 2,744,219 shares and Eli Casdin directly owns 2,901,062 shares. While Standard BioTools is not currently profitable, InvestingPro analysis suggests the stock is slightly undervalued based on its Fair Value assessment. Discover more insights and 7 additional ProTips about LAB in the comprehensive Pro Research Report, available with an InvestingPro subscription.
In other recent news, Standard BioTools Inc. has announced significant changes as part of a restructuring plan aimed at improving operational efficiency. The company has initiated a reduction of approximately 15% of its global workforce, which is expected to incur around $7.5 million in expenses. These costs are primarily related to cash severance, termination benefits, and other related expenses, which will be paid over the coming months. Additionally, Standard BioTools plans to consolidate its research and development operations from South San Francisco to Singapore, leading to further workforce reductions in the U.S., including among management. This consolidation is projected to result in approximately $3.6 million in costs, with $0.9 million attributed to non-cash expenses from share-based awards. The company has noted that these estimates are based on current assumptions and may change as the restructuring progresses. These developments highlight the company’s efforts to align its operations with current revenue projections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.